Evaluation of cell death caused by an ethanolic extract of Serenoae repentis fructus (Prostasan®) on human carcinoma cell lines

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 873-881

  Hostanska, Katarina ^a   Suter, Andy ^b   Melzer, Joerg ^a   Saller, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Bioforce AG   (Switzerland)

Author keywords

Apoptosis; Human cancer cells; Lipidosterolic extract; Proliferation; Serenoa repens

Indexed keywords

ALCOHOL; CRYSTAL VIOLET; FLAVONOID; GENISTEIN; PROSTASAN; QUERCETIN; SABAL EXTRACT; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL GROWTH; CELL VIABILITY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FLOW CYTOMETRY; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FRUIT; HCT116 CELLS; HUMANS; MALE; NEOPLASMS; NEOPLASMS, HORMONE-DEPENDENT; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC NEOPLASMS; SERENOA;

EID: 34247131445     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Boccafoschi C and Annoscia S: Comparison of Serenoa repens extract and placebo in controlled clinical trial in patients with prostatic adematosis. Urologia 50: 1-7, 1983.
2. Gerber GS: Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep 3: 285-291, 2002.
3. European Pharmacopeia (Ph Eur) 5th ed. Stuttgart, Govi Verlag, 2005.
4. Descotes JL, Rambeaud JJ, Deschaseaux P and Faure G: Placebo-controlled evaluation of the efficacy and tolerability of permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 9: 291-297, 1995.
5. Wilt TJ, Ishani A, Rutks I and MacDonald R: Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 3: 459-472, 2000.
6. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A and Perrin P: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate 29: 231-240, 1996.
7. Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R and Raynaud JP: Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 41: 497-507, 2002.
8. Di Silverio F, D'Eramo G, Lubrano C, Flammia GP, Sciarra A, Palma E, Caponera M and Sciarra F: Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign hypertrophy patients. Eur Urol 21: 309-314, 1992.
9. Ravenna L, Di Silverio F, Russo MA, Salvatori L, Morgante E, Morrone S, Cardillo MR, Russo A, Frati L, Gulino A and Petrangeli E: Effect of the lipidosterolic extract of Serenoa repens (Permixon®) on human prostatic cell lines. Prostate 29: 219-230, 1996.
10. Gutierrez M, Garcia de Boto MJ, Cantabrana B and Hidalgo A: Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gen Pharmacol 27: 171-176, 1996.
11. 4) from human polymorphonuclear neutrophils. Prostaglandins, Leukot Essent Fatty Acids 57: 299-304, 1997.
12. Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F and López Farre A: BPH and inflammation: pharmacological effects of permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 44: 549-555, 2003.
13. Bayne CW, Donelly F, Ross M and Habib FK: Serenoa repens (Permixon®): a 5-alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 40: 232-241, 1999.
14. Vacherot F, Azzouz M, Gil-Diez-de-Medina S, Colombel M, De La Taile A, Lefrere Belda MA, Abbou CC, Raynaud JP and Chopin DK: Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon) in benign prostatic hyperplasia. Prostate 45: 259-266, 2000.
15. Goldmann WH, Sharma AL, Currier SJ, Johnston PD, Rana A and Sharma CP: Saw palmetto berry extract inhibits cell growth and COX-2 expression in prostatic cancer cells. Cell Biol Int 11: 1117-1124, 2001.
16. Reed JC: Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 11: 68-75, 1999.
17. Senderowicz AM: Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 16: 670-678, 2004.
18. Hostanska K, Nisslein T, Freudenstein J, Reichling J and Saller R: Apoptosis of human prostate androgen-dependent and -independent carcinoma cells induced by an isopropanolic extract of black cohosh involves degradation of cytokeratin (CK) Anticancer Res 25: 139-148, 2005.
19. Arrends MJ, Mc Gregor AH and Wyllie AH: Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. J Pathol 144: 1045-1057, 1994.
20. Kyprianou N, Tu H and Jacobs SC: Apoptotic vs. proliferative activities in human benign prostatic hyperplasia. Hum Pathol 27: 668-672, 1996.
21. Ellingwood F and Lloyd JU: American material medica, therapeutics and pharmacognosy. Vol. II 1919 Portland: Eclectic Medical Publications, pp. 457-459, 1998.
22. Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM and Braquet P: Effect of the lipidosterolic extract of Serenoa repens (Permixon®) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 33: 340-347, 1998.
23. Bayne CW, Ross M, Donnelly F and Habib FK: The selectivity and specifity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon®) for the prostate. J Urol 164: 876-881, 2000.
24. Iguchi K, Okukura N, Usui S, Sajiki H, Hirota K and Hirano K: Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 47: 59-65, 2001.
25. Hill B and Kyprianou N: Effect of Permixon on human prostate cell growth: lack of apoptotic action. Prostate 61: 73-80, 2004.
26. Vela-Navarrete R, Escribano-Burgos M, Lopez Farre A, Garcia-Cardoso J, Manzarbeita F and Carrasco C: Serenoa repens treatment modifies Bax/Bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J Urol 173: 507-510, 2005.
27. Wadsworth TL, Carroll JM, Mallinson RA, Roberts CT Jr and Roselli CE: Saw Palmetto extract suppresses insulin-like growth factor-I signalling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology 145: 3205-3214, 2004.
28. Ishii K, Usui S, Sugimura Y, Yamamoto H, Yoshikawa K and Hirano K: Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator. Biol Pharm Bull 24: 188-190, 2001.
29. Kapadia GJ, Azuine MA, Tokuda H, Hang E, Mukainaka T, Nishino H and Sridhar R: Inhibitory effect of herbal remedies on 12-O- tetradecanoylphorbol-13-acetate-promoted Epstein-Barr virus early antigen activation. Pharmacol Res 45: 213-220, 2002.